Dendritic cell therapies
The strategy directs the patient’s immune system to recognize the individual repertoire of leukemic antigens without pre-selecting molecular targets.
Source: LinkedIn company description · Retrieved October 13, 2026
Modiblast Pharma is advancing a dendritic cell therapy approach for liquid cancers into the clinical phase.
The company’s stated focus includes addressing relapse after initial treatment for acute myeloid leukemia. The source also identifies myelodysplastic syndrome and other cancers as potential areas for this therapy.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The strategy directs the patient’s immune system to recognize the individual repertoire of leukemic antigens without pre-selecting molecular targets.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026 and September 21, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.